Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 22
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Castle Biosciences Inc
CSTL
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$34.37
1.22
3.68%
Ult. Agg.: Oct 21, 4:00 PM
$34.37
1.22
3.68%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Utili:
I risultati di Q3 2026 tra 14 giorni da adesso in gio nov 5th, dopo la chiusura del mercato
Castle Biosciences Financials
Castle Biosciences (CSTL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Castle Biosciences Raises FY2026 Sales Guidance from $345.000M-$355.000M to $365.000M-$375.000M vs $352.291M Est
Castle Biosciences (NASDAQ:CSTL) raises FY2026 sales outlook from $345.000 million-$355.000 million to $365.000 million-$375.000 million vs $352.291 million estimate.
Benzinga Newsdesk
PRO
Castle Biosciences Q2 Adj. EPS $(0.07) Beats $(0.41) Estimate, Sales $103.546M Beat $86.240M Estimate
Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.41) by 82.93 percent. This is a 146.67 percent decrease over earnings of $0.15 per share
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
Castle Biosciences Raises FY2026 Sales Guidance from $340.000M-$350.000M to $345.000M-$355.000M vs $345.734M Est
Castle Biosciences (NASDAQ:CSTL) raises FY2026 sales outlook from $340.000 million-$350.000 million to $345.000 million-$355.000 million vs $345.734 million estimate.
Benzinga Newsdesk
PRO
Castle Biosciences Q1 Adj. EPS $(0.49), Inline, Sales $83.700M Beat $79.415M Estimate
Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.49) per share which met the analyst consensus estimate. This is a 145 percent decrease over losses of $(0.20) per share from the same period last year.
Benzinga Newsdesk
Castle Biosciences Q4 Earnings Assessment
Benzinga Insights
